X

CTS History

01Dec

Babesia

In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.

About the Author

Related

CTS Business Continuity Plan

CTS Business Continuity Plan

As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...

Read More >

Operational Excellence

CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...

Read More >
Source plasma partners

Source plasma partners

By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...

Read More >
Implementation of a COVID-19 Test

Implementation of a COVID-19 Test

CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...

Read More >
Pooled Babesia

Pooled Babesia

Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...

Read More >
On-time test results

On-time test results

Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...

Read More >